Clinical Trial Update: Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability and pharmacokinetics of single doses of NNC9204-0530 alone and with liraglutide in overweight-to-obese, otherwise …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NNC9204-0530
• liraglutide (liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 1 | Status: COMPLETED